Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis
Sponsored by Pfizer
About this trial
Last updated 17 years ago
Study ID
COXA-0508-243
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18 to 75 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 20 years ago
What is this trial about?
To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac
for the treatment of ankylosing spondylitis
What are the participation requirements?
Inclusion Criteria
- Diagnosis of ankylosing spondylitis defined according to modified New York criteria, and with axial involvement
- Requiring daily treatment with nonsteroidal anti-inflammatory drugs during the previous 30 days
Exclusion Criteria
- Patients with inflammatory enterophathy, and with extra-articular manifestations
- Patients with known vertebral compression
- Received corticosteroids 6 weeks prior to the baseline visit; patients on stable dose of prednisolone equivalents ≤ 10 mg/ day for at least 14 days before randomization were permitted